NXgenPort


NXgenPort is a biomedical technology company focused on developing innovative remote patient monitoring solutions for cancer patients requiring implantable chemo-port catheters. Combining proven efficacy with microchip and sensor technology, NXgenPort aims to enhance early detection of complications, improve patient outcomes, and enable remote management of physiological functions during treatment.

Industries

health-care
medical-device

Nr. of Employees

small (1-50)


Patents

Implantable venous access port with remote physiological monitoring capabilities

US-11771880-B2

View Details

Products

Implantable sensor-enabled port-catheter (prototype, not market authorized)

An implantable port-catheter incorporating miniaturized microelectronic/optical sensors designed to measure physiologic parameters in vivo and transmit data to a remote monitoring platform. Product is in development and has not received market authorization.


Services

Partnerships with healthcare institutions to refine product specifications, plan and execute prototype testing, and design pre-clinical/clinical validation pathways.

Collection, analytics and reporting of device telemetry to provide clinicians with real-time trends, alerts, and actionable reports to support virtual patient management.

Expertise Areas

  • Remote patient monitoring
  • Implantable medical device design
  • Clinical validation and trial support
  • Digital health data analytics and machine learning
  • Show More (4)

Key Technologies

  • Implantable port-catheter devices
  • Microelectronic sensors
  • Optical sensors
  • In‑vivo physiologic monitoring
  • Show More (4)

News & Updates

NXgenPort was awarded the NextGen Award at the 2025 NextMed conference, recognizing its forward-thinking, future-proof solutions in medical technology.

Cathy Skinner shared insights on remote patient monitoring and oncology at a conference in California, highlighting the company's innovative approach.

NXgenPort participated in the Mayo Clinic Platform Accelerate program, building and testing a machine learning algorithm for its device.

NXgenPort was selected to join the 2023 cohort of MedTech Innovator, the world's largest medtech accelerator.

NXgenPort entered into a license agreement with Mayo Clinic to leverage expertise in oncology and digital health to develop its remote monitoring device.

NXgenPort received the NextGen Award at the 2025 NextMed conference for innovative solutions in medical technology.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.